Background. Q fever is a zoonosis caused by Coxiella burnetii. During pregnancy, it may result in obstetric complications, such as spontaneous abortion, intrauterine growth retardation, intrauterine fetal death, and premature delivery. Pregnant women are exposed to the risk of chronic Q fever.
contaminated aerosols. The clinical presentation of Q fever is polymorphic and nonspecific. Q fever may be acute or chronic [8] . Acute Q fever generally presents as a self-limited febrile illness, possibly associated with pneumonia and/or hepatitis, but it can also be asymptomatic [9] [10] [11] . Endocarditis represents the main complication of the chronic form [12] , with fatal evolution in the absence of appropriate treatment [13] . Diagnosis is exclusively based on serologic examination findings [1, 12] . Acute infection results in appearance of IgM and IgG antibodies mainly directed against the avirulent form of C. burnetii (phase II). Chronic Q fever results in particularly high levels of IgG and IgA antibodies directed against both virulent (phase I) and avirulent (phase II) forms of the bacterium [9] .
Few data are available on the consequences of Q fever during pregnancy. To date, only 38 cases have been published [6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , demonstrating that Q fever in pregnant women is associated with high morbidity and mortality. Thus, Q fever during pregnancy can result in spontaneous abortion (26%), intrauterine fetal death (IUFD; 5.3%), premature delivery (44.7%), or intrauterine growth retardation (IUGR; 5.3%). Normal obstetric outcome is possible (15.8%). Transplacental infection of the fetus in utero is possible [22, 24, 30] , but its consequences are still unknown, and its association with obstetric complications remains hypothetical. Q fever during pregnancy also has important consequences for the mother, with higher risk of chronic form [9, 30] and spontaneous abortions of future pregnancies [26] . Finally, Q fever can be reactivated at the time of another pregnancy, requiring regular serological follow-up of these patients [30] .
Treatment of Q fever during pregnancy is a real challenge. Usual treatments, such as doxycycline and quinolone, are contraindicated. Cotrimoxazole and rifampin can be used but do not have bactericidal effects on C. burnetii. Used as short-term treatment, cotrimoxazole was unable to prevent IUFD [33] . For this reason, Raoult et al. [30] have proposed the use of cotrimoxazole therapy during the full duration of pregnancy and have been applying this choice since 1996. Such long-term treatment could prevent IUFD [30] , but its efficacy in the prevention of maternal chronic Q fever has not yet been demonstrated.
The objectives of this study were to evaluate the maternofetal consequences of Q fever during pregnancy. In particular, we evaluated the efficacy of long-term cotrimoxazole therapy.
PATIENTS AND METHODS

Patient characteristics.
All patients who received a diagnosis of Q fever during pregnancy at the French National Reference Center for Rickettsioses (Marseille, France) from 1991 through 2005 entered the study. Seventeen patients who received a diagnosis from 1991 through 2000 were described in previous articles [22, 30] . These patients were contacted by telephone to collect additional data and for follow-up.
For all patients, the physician in charge completed a questionnaire to provide data on epidemiological and clinical features. Past medical history was examined, and patients underwent clinical cardiovascular examinations. If necessary, a cardiac ultrasonograph was performed. For each patient, we recorded the time when Q fever was diagnosed (first, second, or third trimester of pregnancy or after delivery) and the time of infection (before pregnancy or during the first, second, or third trimester of pregnancy). Clinical symptoms of Q fever were noted, as were abnormalities of biological test results, especially thrombocytopenia or increased transaminase levels. Other infectious diseases were excluded on the basis of negative blood culture results and lack of serologic evidence of evolutive infection with Toxoplasma gondii, rubella virus, HIV, hepatitis B, cytomegalovirus, influenza virus, parvovirus B19, adenovirus, Chlamydia species, and Mycoplasma pneumoniae.
Serological diagnosis and isolation of C. burnetii. Phase I and phase II C. burnetii antigens were prepared, and microimmunofluorescence assays were performed, as described elsewhere [1] . Acute Q fever was diagnosed on the basis of an anti-phase II IgG titer у1:200 and an anti-phase II IgM titer у1:50. An anti-phase I IgG titer у1:1600 was required for the diagnosis of chronic Q fever. When collected, placental samples were frozen and stored at Ϫ80ЊC until required for use. Fetal tissue samples were collected in instances of IUFD or termination of pregnancy and were stored under the same conditions as the placental samples. Presence of C. burnetii in placental samples (i.e., placentitis) or on fetal tissue samples was assessed by PCR and culture, as described elsewhere [1] .
Patient treatment and follow-up. Administration of longterm cotrimoxazole treatment, defined as daily oral administration of combined 320 mg of trimethoprim and 1600 mg of sulfamethoxazole for at least 5 weeks of pregnancy, was systematically recorded. When Q fever was diagnosed during pregnancy, serologic testing was performed monthly until delivery. Initial serologic profiles and evolution were recorded as "seroconversion," "acute," or "chronic."
After delivery, patients with "chronic" serologic profiles were treated with a combination of doxycycline (200 mg daily) and hydroxychloroquine (600 mg daily) for 1 year. The dose of hydroxychloroquine was secondarily adapted to the drug plasma level to obtain a value between 0.8 mg/L and 1.2 mg/ L. In accordance with the specific recommendations of hydroxychloroquine use, a specific ophthalmologic examination was performed every 6 months to detect intraretinal accumulation of the molecule. To observe compliance, tolerance, and efficacy of the treatment, all patients received a monthly clinical follow-up visit. Appearance of C. burnetii endocarditis was systematically recorded after being confirmed by transoesophageal cardiac ultrasonograph.
Obstetric outcome. Obstetric data were collected from obstetricians and maternity departments. Patients whose obstetric data could not be collected or were incomplete were excluded from the study. Term, mode of delivery, and birth weight were recorded, as were the following obstetric complications: spontaneous abortion, IUFD, termination of pregnancy, oligoamnios, premature delivery, IUGR, and fetal malformation. Spontaneous abortion was defined as the spontaneous expulsion of the embryo or the fetus before 20 weeks of gestation. IUFD was defined as the intrauterine death of the fetus regardless of the duration of gestation. Oligoamnios was defined as the ultrasonographic measure of an amniotic index р5 cm, according to the technique described by Phelan et al. [31] . IUGR was defined as a fetal birth weight less than the 10th percentile for gestational age, according to the reference growth curves published by Mamelle et al. [32] .
All patients received long-term follow-up to predict maternal and subsequent pregnancy outcomes. Outcomes of subsequent pregnancies were systematically recorded, as was the need for long-term cotrimoxazole therapy. Statistical analysis. Data were analyzed using Fisher's exact test. A P value !.05 was considered to be statistically significant.
RESULTS
Patient characteristics.
From 1991 through 2005, a total of 54 cases of Q fever during pregnancy were diagnosed at the French National Reference Center for Rickettsioses in Marseille, France. Obstetric data of 1 patient could not be collected, and she was excluded from the study. In total, 53 patients were included (table 1) .
Patient characteristics are summarized in table 2. Seventeen patients (32.1%) seroconverted during the study. Of these, 2 patients secondarily developed serologic profiles of acute (patient 7) and chronic (patient 10) infection. In total, 25 patients (47.2%) received diagnoses of acute Q fever, and 28 (52.8%) had serologic profiles that were consistent with chronic Q infection. Fourteen of the 28 patients initially presented with serologic profiles of acute Q fever, and 13 received initial diagnoses of chronic Q infection. Three (10.7%) of the 28 patients who had chronic serologic profiles developed C. burnetii endocarditis. Two of these patients had preexisting heart murmur (patients 13 and 15). One patient received a diagnosis of endocarditis during pregnancy, and maternofetal death occurred at 27 weeks of gestation (patient 15). Endocarditis was diagnosed after delivery in the last 2 patients (patients 8 and 13).
Sixteen patients (30.2%) received long-term cotrimoxazole treatment for a median duration of 16.5 weeks (range, 10-29 weeks). Of the 37 patients who did not receive this therapy, 31 (83.8%) were not treated at all, and 6 (16.2%) received cotrimoxazole for !5 weeks, with a median duration of treatment of 3 weeks (range, 2-4 weeks). Cotrimoxazole treatment had to be stopped because of drug-associated adverse effects in 2 of these 6 patients: 1 patient (patient 15) developed hepatitis, and 1 (patient 33) developed cutaneous rash. Treatment was started just before delivery for 2 patients (patients 10 and 47). For the remaining 2 patients (patients 2 and 22), cotrimoxazole therapy was stopped because of the patient's request, after 3 and 4 weeks of treatment, respectively.
Obstetric outcome. Obstetric complications were observed in 30 (81.1%) of 37 patients who did not receive long-term cotrimoxazole therapy (table 3) . In this group, we observed 5 patients (13.5%) who experienced spontaneous abortions, 10 (27%) who experienced IUFD, and 1 (2.7%) who experienced maternofetal death. Ten women (27%) delivered prematurely, with a median term of 33 weeks (range, 26-36 weeks). IUGR was diagnosed in 10 patients (27%), and oligoamnios was diagnosed in 4 patients (10.8%), with 3 patients experiencing both IUGR and oligoamnios. Termination of pregnancy was performed for 2 patients (patients 39 and 47), at 30 and 26 weeks of gestation, respectively, and was indicated by the combination of severe IUGR and oligoamnios. Two cases of fetal malformation were diagnosed: 1 case of hypospadias (in the newborn of patient 39) and 1 case of Potter syndrome with bilateral renal agenesis, resulting in the immediate death of the newborn after delivery (in the newborn of patient 50). Obstetric complications were found to occur significantly more often in patients who were infected during their first trimester of pregnancy than in those infected later (93.3% vs. 30%; ) P p .032 (table 4) .
Placental and fetal analysis. Placental analysis was performed for 23 patients (table 3) . C. burnetii was identified in 34.8% of analyzed placental samples. All patients who developed placentitis presented with an obstetric complication ( ). IUFD occurred in 4 patients (50%) with placentitis P p .013 and in none of those with an uninfected placenta ( ) P p .008 (table 5) . Fetal tissue samples were obtained from and analyzed for only 4 of the 10 patients with IUFD, and fetal infection was diagnosed in 2 patients (patients 2 and 6). Both of these patients also received a diagnosis of placentitis.
Efficacy of long-term cotrimoxazole therapy. Patients who received long-term cotrimoxazole therapy developed significantly fewer obstetric complications than did those who did not receive this treatment (43.8% vs. 81.1%; ) (table P p .009 3). In particular, no IUFD occurred among patients who received long-term cotrimoxazole therapy, and 27% of those who did not receive this treatment experienced IUFD ( ). P p .018 Long-term cotrimoxazole therapy significantly reduced the rates of placentitis ( ) and chronic Q fever ( ). P p .038 P p .001 Endocarditis was not observed among any of the patients who received long-term cotrimoxazole therapy, but 3 (8.1%) of the 37 patients who did not receive long-term therapy experienced endocarditis (although the difference was not statistically significant).
After delivery, 23 (82.1%) of the 28 patients who developed chronic serologic profiles were given a combination treatment of doxycycline and hydroxychloroquine for 1 year. Two patients with chronic profiles but with identified preexisting valvular pathology also received this therapy (patients 34 and 44). The combination treatment of doxycycline and hydroxychloroquine was administered to significantly fewer patients who had previously been treated with long-term cotrimoxazole therapy ( ) (table 3) . P p .033 Subsequent pregnancies. Nineteen patients had at least 1 subsequent pregnancy (tables 1 and 3), with a total of 25 pregnancies. The median delay until the first subsequent pregnancy was 3 years (range, 1-6 years). All patients who had subsequent pregnancies received regular serologic follow-up examinations. Long-term cotrimoxazole therapy was required for only 6 of 
NOTE.
A, "acute" profile (IgM anti-phase I titer у1:50; IgG anti-phase II titer у1:200); C, "chronic" profile (IgG anti-phase I and II titer у1:1600; IgA antiphase I and II titer у1:100); F, France (other than Marseille and its region); IUGR, intrauterine growth retardation; LC, lost contact; M, Marseille and its region; NP, not performed; O, "seronconversion"; preg, pregnancy; TOP, termination of pregnancy; trim, trimester; und, undetermined.
a By PCR and culture. b By PCR. these patients. All of these patients' pregnancies had normal evolution and outcome.
DISCUSSION
We report here the largest published series about Q fever during pregnancy and essential data on its management. Analysis of our patients reveals that Q fever during pregnancy is a significant cause of morbidity and mortality and can therefore result in spontaneous abortion, IUGR, IUFD, or premature delivery. We also describe, for the first time, Q fever as a possible cause of oligoamnios, which is known to be associated with high neonatal morbidity and mortality [33] [34] [35] [36] . Previous observation of Q fever during pregnancy suggests that the pathogenesis of fetal death may be caused by direct fetal infection, because C. burnetii has been identified in the placenta and also in fetal viscera [22] . In our study, all patients with identified placentitis developed obstetric complications ( ). Moreover, all 4 cases of IUFD were observed in the P p .013 pregnant patients who had placentitis; placentitis was not observed in the 15 patients whose newborns were alive at delivery ( ). Our data, therefore, illustrate for the first time the P p .008 link between placentitis and obstetric complications and the abortifacient potential of C. burnetii infection in humans. However, C. burnetii was not identified in all placental samples collected from women with obstetric complications. Such results could be explained by insufficient sensitivity of PCR and culture technique or by focal placental infection. Because pregnant women in whom placentitis was identified had a higher rate of IUFD, it may be hypothesized that these cases of placentitis corresponded with a higher bacterial load in the placenta and/or to a systemic infection.
To date, teratogenicity has never been associated with C. burnetii infection. In our study, 2 newborns were delivered with malformations. The first newborn had hypospadias associated with severe IUGR and oligoamnios (newborn of patient 39). Hypospadias is the most common fetal genital malformation, occurring in 0.5%-4% of male newborns [33] . It is significantly correlated with the presence of IUGR [37, 38] , and no infectious etiology is known [39] . The second newborn had Potter syndrome (newborn of patient 50), which usually leads to lung hypoplasia and early neonatal death [40, 41] . Its etiology remains unknown, although some familial cases have been described, which could evoke a possible genetic cause [42] . In both cases, there was no evidence of direct relation with C. burnetii infection, and these malformations were probably fortuitous. Q fever during pregnancy also exposes the mother to severe complications. Among the 53 patients in our study, 52.8% developed "chronic" serologic profiles, although this usually concerns only 5% of the global population [1] . It seems that the main risk factor for the chronic form of Q fever is the duration of infection during pregnancy and that patients more often develop a "chronic" serologic profile when infected during their first trimester of pregnancy [30] . In our study, 80% of the patients infected during their first trimester of pregnancy developed chronic Q fever, which is almost double the rate observed among patients infected later during pregnancy. However, this difference was not significant ( ), and a larger P p .079 study is needed to correctly evaluate this hypothesis.
Q fever treatment is difficult. C. burnetii is an obligatory intracellular bacterium that lives in acidic vacuoles (phagolysosomes), which may protect it from the bactericidal effects of antibiotics [43] . Because chloroquine raises the pH in the phagolysosome, restoring the bacteriocidal effect of doxycycline, the combination of doxycycline and chloroquine is the only effective bactericidal regimen in vitro [43, 44] . Both doxycycline and chloroquine are contraindicated during pregnancy. Despite a theoretical risk of neonatal bilirubinemia when used just before delivery [45] , cotrimoxazole may be used but has only a bacteriostatic effect. Because a 3-week cotrimoxazole treatment regimen did not prevent IUFD (e.g., in patient 2) [22] , Raoult et al. [30] proposed the use of long-term cotrimoxazole therapy and have applied this choice since 1996.
Our data show, for the first time, the ability of long-term cotrimoxazole therapy to prevent maternofetal complications of Q fever during pregnancy. According to our experience, this ). Obstetric complications were still observed in P p .001 43.8% of pregnant women receiving long-term cotrimoxazole therapy. But in this group, the only complications observed were IUGR and premature delivery, and we did not observe any cases of spontaneous abortion, oligoamnios, or IUFD. The difference in the mean duration of cotrimoxazole therapy cannot explain this situation, because it was equivalent for patients who did and did not present with obstetric complications (mean duration of cotrimoxazole therapy, 18 weeks vs. 17.6 weeks; the difference was not statistically significant). When administered for a minimum of 5 weeks, cotrimoxazole therapy also prevents the need for postpartum treatment with a combination of doxycycline and hydroxychloroquine ( ). P p .033 Although the observed difference between the rate of endocarditis among patients treated with long-term cotrimoxazole and that in untreated patients was not statistically significant, endocarditis was not diagnosed in any of the patients who were given this therapy. Endocarditis is the major complication of chronic Q fever [1] . By preventing the evolution toward a chronic serologic profile, it is probable that long-term cotrimoxazole therapy also prevents C. burnetii endocarditis.
In this study, we report our 15 years' experience of diagnosis and management of Q fever during pregnancy. Because this was not a randomized trial, interpretation of our results must be careful. Women who received a diagnosis of Q fever before 1996 did not receive long-term cotrimoxazole therapy. After this date, patients who did not receive this therapy were mostly patients who received a diagnosis of Q fever just before delivery or retrospectively after delivery, often because of the occurrence of obstetric complications. This explains why diagnoses were made significantly later in untreated or insufficiently treated women (table 2) . Because the diagnosis of Q fever in patients who did not receive long-term cotrimoxazole therapy was sought significantly more often because of existing obstetric complications (table 2) , interpretation of our results is limited by a selection bias. When considering only the 37 patients who did not present with obstetric complications at the time of diagnosis, we still observed a significant efficacy of long-term cotrimoxazole therapy to prevent IUFD ( ) and chronic P p .047 maternal Q fever ( ). For this reason, although a pro-P p .039 spective randomized trial is warranted to confirm our results, we believe that long-term cotrimoxazole therapy should be systematically administered to women with Q fever during pregnancy.
During pregnancy, Q fever is a significant cause of morbidity and mortality, both for the fetus and the mother, and is more serious when it occurs early. Q fever exposes the fetus to spontaneous abortion, IUGR, IUFD, premature delivery, and oligoamnios. Occurrence of IUFD is correlated with the presence of placentitis. The mother is exposed to the risk of chronic Q fever and endocarditis. Long-term cotrimoxazole therapy is efficacious in preventing IUFD. It also prevents development of a "chronic" serologic profile in the mother. For these reasons, long-term cotrimoxazole therapy should be administered to all pregnant women who have proven Q fever.
